Biohaven Ltd. (BHVN) Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development, and commercialization of treatments in immunology, neuroscience, and oncology. The company operates as a pre-revenue entity, funding operations through cash reserves and equity financing. As of June 30, 2024, the company had 92,346,332 common shares outstanding.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(319.8) million | $(90.3) million | $(499.3) million | $(160.8) million |
| Net Loss Per Share (Basic/Diluted) | $(3.64) | $(1.32) | $(5.93) | $(2.36) |
| Research & Development Expenses | $314.8 million | $79.5 million | $470.8 million | $143.0 million |
| General & Administrative Expenses | $19.0 million | $14.5 million | $46.2 million | $28.8 million |
| Cash, Cash Equivalents & Marketable Securities | $436.9 million (as of June 30, 2024) | |||
| Net Cash Used in Operating Activities (YTD) | $(270.4) million | |||
| Net Cash Provided by Financing Activities (YTD) | $324.5 million |
Material Changes vs. Prior Period
- Significant Increase in R&D Expenses: R&D expenses surged by $235.3 million in Q2 2024 compared to Q2 2023. This was primarily driven by a one-time non-cash expense of $171.9 million related to the "Knopp Amendment," which involved a milestone and royalty buyback for the BHV-7000 (Kv7) platform. This transaction reduced potential future milestone payments by $867.5 million.
- Other Income, Net: Increased to $14.2 million in Q2 2024 from $5.8 million in Q2 2023. This increase was largely due to a $9.2 million gain recorded upon the settlement of a forward contract liability related to the Knopp Amendment, alongside increased investment income.
- Share-Based Compensation: Non-cash share-based compensation expense increased significantly to $12.2 million in Q2 2024 (up from $4.7 million in Q2 2023) due to annual equity incentive awards granted in late 2023 and early 2024.
- Derivative Liabilities: The company recorded $93.4 million in forward contract and derivative liabilities as of June 30, 2024, related to the Knopp Amendment (2024 and 2025 Additional Considerations and True-ups). No such liabilities were recorded as of December 31, 2023.
Guidance, Outlook, and Risks
- Liquidity: Management expects existing cash, cash equivalents, and marketable securities ($436.9 million) to be sufficient to fund operations for at least one year beyond the filing date. However, the company expects to incur significant operating losses for the foreseeable future and will require additional capital to fund clinical trials and commercialization.
- Clinical Pipeline Updates:
- Troriluzole (BHV-4157): Phase 3 trials in OCD are ongoing; topline data expected in H1 2025. A new Real-World Evidence (RWE) protocol for SCA3 is underway, with topline data expected in H2 2024.
- Taldefgrobep Alfa (BHV-2000): Phase 3 trial in Spinal Muscular Atrophy (SMA) is ongoing; topline data expected in H2 2024. A Phase 2 trial for metabolic disorders (obesity) is planned for H2 2024.
- BHV-7000 (Kv7): Phase 2/3 trials in focal epilepsy and idiopathic generalized epilepsy have commenced. Phase 2 trials for Major Depressive Disorder and Bipolar Disorder initiated in Q2 2024.
- BHV-2100 (TRPM3): Phase 1 data positive; Phase 2 studies for migraine and neuropathic pain planned for H2 2024.
- BHV-1510 (TROP-2 ADC): Acquired via Pyramid Biosciences; Phase 1/2 trial in advanced solid tumors commenced in Q2 2024.
- Capital Raising: In April 2024, the company completed a public offering raising approximately $247.8 million. Additionally, under an Equity Distribution Agreement, the company raised approximately $146.3 million through August 9, 2024, exhausting the available capacity under that agreement.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional financing, and the volatility of derivative liabilities tied to the company's stock price (Knopp Amendment true-ups).
Investor Verification Checklist
- Knopp Amendment Impact: Verify the long-term financial impact of the $171.9 million non-cash expense and the remaining $93.4 million in derivative liabilities, specifically how stock price volatility affects future earnings via the "true-up" provisions.
- Cash Burn Rate: Assess the sustainability of the current cash position ($436.9 million) against the accelerating R&D spend, particularly with multiple Phase 3 trials underway.
- Troriluzole Regulatory Path: Monitor the outcome of the FDA's review of the new Real-World Evidence protocol for SCA3, given the previous "refuse-to-file" decision on the NDA.
- Equity Dilution: Review the impact of recent equity issuances (April 2024 offering and ATM sales) on shareholder dilution and the company's ability to raise further capital without excessive dilution.
- Pyramid Acquisition Integration: Track the progress of the BHV-1510 (TROP-2 ADC) program acquired from Pyramid Biosciences, including the milestone payments and clinical trial enrollment.